Utilization management programs for atopic dermatitis may hinder patient care, causing treatment delays and increased costs despite advances in biologic therapies.
Jeffery D. Dunn, PharmD, MBA
Advertisement
Articles by Jeffery D. Dunn, PharmD, MBA
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 2b Analysis Shows Consistent Vitiligo Repigmentation With Ritlecitinib
2
Litifilimab Shows Early Skin Benefits in CLE
3
Dual ITK/JAK3 Inhibition Shows Strong Preclinical Activity in Severe Alopecia Areata
4
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
5